Daniel Mark Blumenthal, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Faculty, Medical | 10 | 2020 | 1192 | 1.910 |
Why?
|
Schools, Medical | 7 | 2020 | 878 | 1.370 |
Why?
|
Career Mobility | 4 | 2020 | 258 | 1.230 |
Why?
|
Medicare Part C | 3 | 2022 | 322 | 1.220 |
Why?
|
Physicians, Women | 7 | 2020 | 492 | 1.200 |
Why?
|
Angina Pectoris | 2 | 2021 | 969 | 1.040 |
Why?
|
Internal Medicine | 4 | 2019 | 1045 | 0.830 |
Why?
|
Reimbursement, Incentive | 3 | 2018 | 543 | 0.810 |
Why?
|
Sex Distribution | 5 | 2019 | 2295 | 0.800 |
Why?
|
Reimbursement Mechanisms | 2 | 2018 | 664 | 0.790 |
Why?
|
Medicare | 14 | 2021 | 6771 | 0.760 |
Why?
|
Mandatory Reporting | 2 | 2018 | 124 | 0.670 |
Why?
|
Hospital Mortality | 8 | 2019 | 5420 | 0.660 |
Why?
|
Coronary Artery Disease | 6 | 2021 | 6661 | 0.650 |
Why?
|
Prescriptions | 1 | 2021 | 388 | 0.640 |
Why?
|
Quality of Health Care | 7 | 2018 | 4361 | 0.630 |
Why?
|
Contract Services | 1 | 2017 | 89 | 0.590 |
Why?
|
Allergy and Immunology | 1 | 2019 | 175 | 0.590 |
Why?
|
Salaries and Fringe Benefits | 2 | 2017 | 258 | 0.590 |
Why?
|
Myocardial Infarction | 6 | 2018 | 11891 | 0.580 |
Why?
|
Biopharmaceutics | 1 | 2016 | 23 | 0.560 |
Why?
|
Hospitals | 5 | 2018 | 3929 | 0.550 |
Why?
|
Leadership | 4 | 2020 | 1372 | 0.550 |
Why?
|
Health Care Reform | 2 | 2024 | 1245 | 0.550 |
Why?
|
United States | 43 | 2024 | 72363 | 0.540 |
Why?
|
Episode of Care | 1 | 2016 | 127 | 0.530 |
Why?
|
Hospitals, Proprietary | 1 | 2015 | 39 | 0.510 |
Why?
|
Prescription Fees | 1 | 2016 | 151 | 0.510 |
Why?
|
Hospitalists | 2 | 2018 | 295 | 0.500 |
Why?
|
Arthroplasty, Replacement | 1 | 2018 | 310 | 0.500 |
Why?
|
Foreign Medical Graduates | 3 | 2021 | 77 | 0.480 |
Why?
|
Certification | 1 | 2017 | 423 | 0.460 |
Why?
|
Hypolipidemic Agents | 1 | 2017 | 626 | 0.420 |
Why?
|
Ownership | 1 | 2015 | 339 | 0.420 |
Why?
|
Hospital Costs | 2 | 2024 | 976 | 0.420 |
Why?
|
Program Development | 3 | 2014 | 1297 | 0.410 |
Why?
|
Postoperative Hemorrhage | 1 | 2016 | 422 | 0.400 |
Why?
|
Drug Costs | 2 | 2017 | 1184 | 0.390 |
Why?
|
Angina, Unstable | 1 | 2016 | 926 | 0.380 |
Why?
|
Interviews as Topic | 1 | 2018 | 2656 | 0.370 |
Why?
|
Patient Readmission | 7 | 2019 | 3327 | 0.370 |
Why?
|
Economics, Hospital | 1 | 2013 | 212 | 0.370 |
Why?
|
Hospitalization | 5 | 2024 | 10761 | 0.360 |
Why?
|
Health Care Costs | 4 | 2024 | 3257 | 0.350 |
Why?
|
Appetite Regulation | 1 | 2010 | 84 | 0.350 |
Why?
|
Sex Factors | 7 | 2020 | 10530 | 0.340 |
Why?
|
Nervous System Physiological Phenomena | 1 | 2010 | 114 | 0.340 |
Why?
|
Drug-Eluting Stents | 1 | 2016 | 758 | 0.330 |
Why?
|
Coronary Artery Bypass | 1 | 2018 | 2273 | 0.320 |
Why?
|
Motivation | 1 | 2018 | 1990 | 0.320 |
Why?
|
Physicians | 7 | 2021 | 4590 | 0.310 |
Why?
|
Critical Care | 2 | 2017 | 2699 | 0.290 |
Why?
|
Curriculum | 3 | 2016 | 3722 | 0.280 |
Why?
|
Colonoscopy | 1 | 2015 | 1387 | 0.280 |
Why?
|
Health Expenditures | 1 | 2018 | 2359 | 0.260 |
Why?
|
Fee-for-Service Plans | 4 | 2019 | 705 | 0.260 |
Why?
|
Cross-Sectional Studies | 11 | 2021 | 25928 | 0.260 |
Why?
|
Delivery of Health Care | 1 | 2024 | 5324 | 0.260 |
Why?
|
Length of Stay | 2 | 2017 | 6472 | 0.260 |
Why?
|
Behavior, Addictive | 1 | 2010 | 462 | 0.240 |
Why?
|
Primary Health Care | 1 | 2021 | 4649 | 0.240 |
Why?
|
Patient Compliance | 1 | 2015 | 2689 | 0.230 |
Why?
|
Attitude of Health Personnel | 1 | 2018 | 3870 | 0.230 |
Why?
|
Humans | 57 | 2024 | 760261 | 0.220 |
Why?
|
Coronary Angiography | 1 | 2015 | 4560 | 0.220 |
Why?
|
Quality Improvement | 2 | 2018 | 3840 | 0.220 |
Why?
|
Male | 40 | 2024 | 359413 | 0.220 |
Why?
|
Cardiovascular Diseases | 4 | 2024 | 15740 | 0.210 |
Why?
|
Quality Assurance, Health Care | 4 | 2019 | 2178 | 0.210 |
Why?
|
Female | 40 | 2024 | 391011 | 0.210 |
Why?
|
Education, Medical, Graduate | 1 | 2014 | 2359 | 0.200 |
Why?
|
Electronic Health Records | 3 | 2023 | 4763 | 0.200 |
Why?
|
Clinical Competence | 4 | 2021 | 4786 | 0.200 |
Why?
|
Risk Assessment | 6 | 2018 | 24086 | 0.200 |
Why?
|
Patient Care Team | 1 | 2013 | 2510 | 0.190 |
Why?
|
Subtilisins | 1 | 2021 | 82 | 0.190 |
Why?
|
Aged | 28 | 2024 | 168995 | 0.190 |
Why?
|
Insurance Coverage | 2 | 2022 | 1939 | 0.180 |
Why?
|
Internship and Residency | 3 | 2019 | 5867 | 0.170 |
Why?
|
Endoribonucleases | 1 | 2021 | 229 | 0.170 |
Why?
|
Medicine | 2 | 2020 | 943 | 0.170 |
Why?
|
Cost Control | 1 | 2022 | 630 | 0.160 |
Why?
|
Golf | 1 | 2018 | 16 | 0.160 |
Why?
|
Health Benefit Plans, Employee | 1 | 2022 | 333 | 0.160 |
Why?
|
Health Facility Size | 1 | 2018 | 62 | 0.160 |
Why?
|
Aged, 80 and over | 11 | 2024 | 58947 | 0.160 |
Why?
|
Professional Misconduct | 1 | 2018 | 73 | 0.150 |
Why?
|
Fraud | 1 | 2018 | 66 | 0.150 |
Why?
|
Vinculin | 1 | 2018 | 59 | 0.150 |
Why?
|
Talin | 1 | 2018 | 46 | 0.150 |
Why?
|
Feeding Behavior | 1 | 2010 | 3185 | 0.150 |
Why?
|
Odds Ratio | 3 | 2020 | 9712 | 0.150 |
Why?
|
Immunological Synapses | 1 | 2018 | 59 | 0.150 |
Why?
|
Health Services Accessibility | 1 | 2015 | 5396 | 0.150 |
Why?
|
Integrin alpha4beta1 | 1 | 2018 | 119 | 0.150 |
Why?
|
Gynecology | 1 | 2023 | 534 | 0.150 |
Why?
|
Professional Practice Location | 1 | 2017 | 57 | 0.140 |
Why?
|
Industry | 1 | 2019 | 361 | 0.140 |
Why?
|
Equipment and Supplies | 1 | 2019 | 275 | 0.140 |
Why?
|
Evidence-Based Practice | 2 | 2019 | 495 | 0.140 |
Why?
|
Medicare Part D | 1 | 2021 | 354 | 0.140 |
Why?
|
Age Distribution | 3 | 2018 | 2893 | 0.130 |
Why?
|
Cardiology Service, Hospital | 1 | 2018 | 242 | 0.130 |
Why?
|
Community-Based Participatory Research | 1 | 2018 | 221 | 0.130 |
Why?
|
Middle Aged | 20 | 2024 | 220175 | 0.130 |
Why?
|
Multivariate Analysis | 3 | 2020 | 12156 | 0.130 |
Why?
|
Efficiency | 1 | 2018 | 477 | 0.130 |
Why?
|
Specialization | 2 | 2018 | 779 | 0.120 |
Why?
|
Achievement | 1 | 2016 | 289 | 0.120 |
Why?
|
Public Sector | 1 | 2016 | 265 | 0.120 |
Why?
|
Heart Failure | 2 | 2019 | 11835 | 0.120 |
Why?
|
Secondary Prevention | 1 | 2021 | 1548 | 0.120 |
Why?
|
Emigration and Immigration | 1 | 2017 | 395 | 0.120 |
Why?
|
Acute Coronary Syndrome | 2 | 2018 | 2362 | 0.120 |
Why?
|
Prescription Drugs | 1 | 2021 | 630 | 0.110 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2017 | 498 | 0.110 |
Why?
|
Public Policy | 1 | 2017 | 560 | 0.110 |
Why?
|
Hospitals, Teaching | 1 | 2018 | 1166 | 0.110 |
Why?
|
Congresses as Topic | 1 | 2018 | 804 | 0.110 |
Why?
|
Retrospective Studies | 9 | 2024 | 80301 | 0.110 |
Why?
|
Emergency Medicine | 2 | 2019 | 1195 | 0.100 |
Why?
|
Employee Performance Appraisal | 1 | 2013 | 86 | 0.100 |
Why?
|
Health Facilities | 1 | 2017 | 578 | 0.100 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20484 | 0.100 |
Why?
|
Needs Assessment | 1 | 2018 | 1137 | 0.100 |
Why?
|
Adult | 16 | 2024 | 219847 | 0.100 |
Why?
|
Communicable Diseases | 1 | 2020 | 879 | 0.090 |
Why?
|
Patient Satisfaction | 2 | 2015 | 3451 | 0.090 |
Why?
|
Hyperlipidemias | 1 | 2016 | 782 | 0.090 |
Why?
|
Physician-Patient Relations | 1 | 2024 | 3242 | 0.090 |
Why?
|
Dyspnea | 1 | 2018 | 1352 | 0.090 |
Why?
|
Health Services Research | 4 | 2018 | 1811 | 0.090 |
Why?
|
Health Personnel | 1 | 2024 | 3310 | 0.090 |
Why?
|
Surgical Procedures, Operative | 1 | 2021 | 1919 | 0.090 |
Why?
|
Exercise Test | 1 | 2018 | 2125 | 0.090 |
Why?
|
Angioplasty | 1 | 2012 | 360 | 0.090 |
Why?
|
Patient Care Management | 1 | 2013 | 303 | 0.080 |
Why?
|
Logistic Models | 3 | 2020 | 13311 | 0.080 |
Why?
|
Anticholesteremic Agents | 1 | 2016 | 988 | 0.080 |
Why?
|
Publishing | 1 | 2016 | 837 | 0.080 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2018 | 2536 | 0.080 |
Why?
|
Regression Analysis | 1 | 2018 | 6361 | 0.080 |
Why?
|
Follow-Up Studies | 3 | 2018 | 39254 | 0.080 |
Why?
|
Job Satisfaction | 1 | 2012 | 539 | 0.080 |
Why?
|
Feasibility Studies | 1 | 2018 | 5201 | 0.070 |
Why?
|
Lymphocyte Activation | 1 | 2018 | 5498 | 0.070 |
Why?
|
General Surgery | 1 | 2018 | 1681 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4875 | 0.070 |
Why?
|
Cholesterol, LDL | 1 | 2016 | 2422 | 0.070 |
Why?
|
Program Evaluation | 1 | 2014 | 2494 | 0.070 |
Why?
|
Health Status Disparities | 1 | 2018 | 1819 | 0.070 |
Why?
|
Medicaid | 2 | 2019 | 2811 | 0.070 |
Why?
|
Natural Language Processing | 1 | 2015 | 1136 | 0.070 |
Why?
|
Quality of Life | 2 | 2018 | 13300 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2018 | 4355 | 0.060 |
Why?
|
Cost-Benefit Analysis | 1 | 2017 | 5507 | 0.060 |
Why?
|
Postoperative Complications | 2 | 2018 | 15680 | 0.060 |
Why?
|
Home Care Services, Hospital-Based | 1 | 2024 | 45 | 0.060 |
Why?
|
Intensive Care Units | 1 | 2017 | 3737 | 0.060 |
Why?
|
Academic Medical Centers | 1 | 2014 | 2753 | 0.060 |
Why?
|
Prevalence | 1 | 2021 | 15687 | 0.060 |
Why?
|
Survival Rate | 1 | 2018 | 12806 | 0.060 |
Why?
|
Drug Industry | 2 | 2021 | 789 | 0.060 |
Why?
|
Metabolic Diseases | 1 | 2010 | 685 | 0.060 |
Why?
|
Radiology | 1 | 2017 | 2103 | 0.060 |
Why?
|
Food | 1 | 2008 | 772 | 0.060 |
Why?
|
Commerce | 1 | 2008 | 604 | 0.050 |
Why?
|
Pennsylvania | 1 | 2024 | 615 | 0.050 |
Why?
|
Models, Theoretical | 1 | 2015 | 3561 | 0.050 |
Why?
|
Food Supply | 1 | 2008 | 542 | 0.050 |
Why?
|
Treatment Outcome | 6 | 2018 | 64947 | 0.050 |
Why?
|
Pilot Projects | 1 | 2014 | 8553 | 0.050 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 3333 | 0.050 |
Why?
|
Prognosis | 2 | 2018 | 29636 | 0.050 |
Why?
|
Ribonucleases | 1 | 2021 | 277 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2017 | 10340 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2016 | 8058 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2016 | 9196 | 0.040 |
Why?
|
Depression | 1 | 2018 | 8033 | 0.040 |
Why?
|
Databases, Factual | 3 | 2018 | 8018 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7809 | 0.040 |
Why?
|
Paxillin | 1 | 2018 | 86 | 0.040 |
Why?
|
Cluster Analysis | 1 | 2024 | 2698 | 0.040 |
Why?
|
Community Health Planning | 1 | 2018 | 165 | 0.040 |
Why?
|
Health Services Misuse | 1 | 2018 | 245 | 0.030 |
Why?
|
Cohort Studies | 4 | 2023 | 41317 | 0.030 |
Why?
|
Lymphocyte Function-Associated Antigen-1 | 1 | 2018 | 377 | 0.030 |
Why?
|
Jurkat Cells | 1 | 2018 | 736 | 0.030 |
Why?
|
Protein Multimerization | 1 | 2021 | 983 | 0.030 |
Why?
|
Lipoproteins, LDL | 1 | 2019 | 641 | 0.030 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2018 | 694 | 0.030 |
Why?
|
Neoplasms | 1 | 2024 | 22066 | 0.030 |
Why?
|
Research Support as Topic | 1 | 2019 | 699 | 0.030 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2018 | 1128 | 0.030 |
Why?
|
Substance-Related Disorders | 1 | 2010 | 4370 | 0.030 |
Why?
|
Tyrosine | 1 | 2018 | 1440 | 0.030 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2019 | 1256 | 0.030 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2019 | 1025 | 0.030 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2018 | 572 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 1521 | 0.030 |
Why?
|
Time Factors | 3 | 2019 | 40133 | 0.020 |
Why?
|
Models, Molecular | 1 | 2021 | 5429 | 0.020 |
Why?
|
Canada | 1 | 2016 | 2128 | 0.020 |
Why?
|
Age Factors | 2 | 2018 | 18415 | 0.020 |
Why?
|
Chest Pain | 1 | 2018 | 1106 | 0.020 |
Why?
|
Internationality | 1 | 2016 | 1005 | 0.020 |
Why?
|
Genetic Testing | 1 | 2023 | 3530 | 0.020 |
Why?
|
Actins | 1 | 2018 | 2049 | 0.020 |
Why?
|
Communication | 1 | 2024 | 3846 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2020 | 2627 | 0.020 |
Why?
|
Stents | 1 | 2021 | 3303 | 0.020 |
Why?
|
Nutrition Surveys | 1 | 2016 | 1727 | 0.020 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2021 | 3201 | 0.020 |
Why?
|
Connecticut | 1 | 2008 | 364 | 0.020 |
Why?
|
Cardiology | 1 | 2019 | 1723 | 0.020 |
Why?
|
Incidence | 2 | 2016 | 21378 | 0.020 |
Why?
|
Cell Line | 1 | 2021 | 15626 | 0.020 |
Why?
|
Phosphorylation | 1 | 2018 | 8314 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2017 | 2283 | 0.020 |
Why?
|
Risk | 1 | 2018 | 9629 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 3696 | 0.020 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2019 | 2296 | 0.010 |
Why?
|
Education, Medical | 1 | 2016 | 1728 | 0.010 |
Why?
|
Comorbidity | 1 | 2019 | 10552 | 0.010 |
Why?
|
Survival Analysis | 1 | 2016 | 10185 | 0.010 |
Why?
|
Blood Pressure | 1 | 2019 | 8523 | 0.010 |
Why?
|
Vegetables | 1 | 2008 | 1198 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7468 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2018 | 16905 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 5884 | 0.010 |
Why?
|
Income | 1 | 2008 | 1876 | 0.010 |
Why?
|
Risk Factors | 2 | 2018 | 74269 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2008 | 2058 | 0.010 |
Why?
|
Animals | 1 | 2010 | 167940 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2016 | 20048 | 0.010 |
Why?
|
Health Policy | 1 | 2008 | 2678 | 0.010 |
Why?
|
Signal Transduction | 1 | 2018 | 23363 | 0.010 |
Why?
|
Prospective Studies | 1 | 2018 | 54263 | 0.010 |
Why?
|
Young Adult | 1 | 2018 | 58673 | 0.010 |
Why?
|
Adolescent | 1 | 2018 | 87747 | 0.010 |
Why?
|